GRPR and neoplasm: Similar to [68Ga]Ga-TacsBOMB2 and [68Ga]Ga-TacsBOMB3, the derived [68Ga]Ga-TacBOMB2 and [68Ga]Ga-TacBOMB3 agonist PET tracers also retain in vivo GRPR-targeting capabilities, as demonstrated by their good tumor uptake and tumor-to-background contrast ratios in imaging and biodistribution studies.